A novel immunotherapy for superficial bladder cancer by the immobilization of streptavidin-tagged bioactive IL-2 on the biotinylated mucosal surface of the bladder wall

Chinese Journal of Cancer

Volumn 29, Issue 6, 2010, Pages 611-616

  Huang, Xin ^a   Yu, Hong sheng ^b   Chen, Zhong ^a   Li, Jin Long ^a   Hu, Zhi Ming ^a   Gao, Ji Min ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Immunotherapy; Interleukin 2; Streptavidin; Superficial bladder cancer

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 2; STREPTAVIDIN RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTINYLATION; BLADDER CANCER; BLADDER WALL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN IMMOBILIZATION; TUMOR GROWTH; WILD TYPE;

EID: 79955820561     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.009.10640     Document Type: Article

References (10)

1. Malek TR, Yu A, Zhu L, et al. IL-2 family of cytokines in T regulatory cell development and homeostasis [J]. J Clin Immunol, 2008, 28(6): 635-639.
2. Sano T, Cantor CR. Streptavidin-containing chimeric proteins: design and production [J]. Methods Enzymol, 2000, 326: 305-311.
3. Liang ZK, Zhang L, Hu ZM, et al. A simple and efficient method for establishing a mouse model of orthotopic MB49 bladder cancer [J]. J South Med Univ, 2009, 29(4): 627-630. [in Chinese]
4. Zhang L, Hu ZM, Fa PP, et al. Preparation and characterization of SA-hIL2 fusion protein [J]. China Biotechnology, 2009, 29 (7): 12-16. [in Chinese]
5. Lamm DL, Mc Gee WR, Hale K. Bladder cancer: current optimal intravesical treatment [J]. Urol Nurs, 2005, 25(5): 323-326
6. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story [J]. J Urol, 2008, 179(1): 53-56.
7. Sosnowski JT, DeHaven JI, Riggs DR, et al. Treatment of murine transitional cell carcinoma with intralesional interleukin 2 and murine interferon gamma [J]. J Urol, 1991, 146(4): 1164-1167.
8. Huland E, Huland H. Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma [J]. Cancer Res, 1989, 49(19): 5469-5474.
9. Gao J, Huang S, Li M, et al. GM-CSF-modified mouse B16. F10 melanoma whole cell vaccine [J]. Vaccine, 2006, 24(25): 5265-5268.
10. Paganelli G, Grana C, Chinol M, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin [J]. Eur J Nucl Med, 1999, 26(4): 348-357.